文献速递肝病消化道肿瘤与早癌

高心血管风险与MASLD肝纤维化进展及肝脏事件风险

Progression of Liver Fibrosis and Liver-Related Event Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease at High Cardiovascular Risk.
PubMed 文献 · Clin Gastroenterol Hepatol · 2026-02-06

基于VCTE-Prognosis队列9312例MASLD患者,用FRS、PCE、PREVENT评估心血管风险分层。高心血管风险与进展期肝纤维化患病率、肝硬度进展及肝脏相关事件发生率升高相关。

要点

  • 高心血管风险MASLD患者进展期肝纤维化患病率更高
  • 中位随访4.5年,5.0%患者肝硬度进展,高危组更常见
  • 肝脏相关事件发生率为1.4%,高危组发生率更高

核心结论

  • 在MASLD患者中,心血管风险越高,进展期肝纤维化患病率、肝硬度进展和肝脏相关事件发生率越高。

研究设计与样本

  • 来自VCTE-Prognosis队列的MASLD患者9312例,平均年龄54.4±11.0岁,男性56.8%,亚洲人87.4%。
  • 用FRS、PCE或PREVENT评分将患者分为低、中、高心血管风险类别。
  • 结局包括进展期纤维化(肝硬度≥10 kPa)患病率、肝硬度进展(增加≥20%及Baveno类别上调)和肝脏相关事件。
  • 采用多变量logistic回归和Fine-Gray竞争风险模型评估关联。

主要发现

  • 进展期纤维化患病率随心血管风险升高:FRS调整OR 2.72(95%CI 2.25-3.28,P<.001),PCE调整OR 1.83(95%CI 1.46-2.29,P<.001),PREVENT调整OR 2.93(95%CI 2.33-3.69,P<.001)。
  • 中位随访4.5年,5.0%患者出现肝硬度进展,高危组更常见:PCE调整SHR 1.56(95%CI 1.14-2.15,P=.006),PREVENT调整SHR 1.85(95%CI 1.33-2.56,P<.001)。
  • 肝脏相关事件发生于1.4%患者,高危组发生率更高:FRS调整SHR 2.12(95%CI 1.19-3.77,P=.010),PCE调整SHR 2.01(95%CI 1.08-3.74,P=.027),PREVENT调整SHR 2.80(95%CI 1.40-5.61,P=.004)。

关键数值与推荐

  • 进展期纤维化定义为肝硬度≥10 kPa。
  • 肝硬度进展定义为增加≥20%及Baveno类别上调。
  • 肝脏相关事件包括肝细胞癌、肝功能失代偿、肝移植或肝脏相关死亡。

临床怎么用

  • 对MASLD患者可结合FRS、PCE或PREVENT评估心血管风险,高心血管风险者应关注肝纤维化筛查与随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and high cardiovascular risk often have advanced liver fibrosis, but data on associations and outcomes are limited. The aim of this study was to evaluate the relationships between cardiovascular risk categories and liver fibrosis severity, liver fibrosis progression, and liver-related events (LREs) in MASLD. METHODS: Patients with MASLD from the VCTE-Prognosis cohort were stratified into low, intermediate, and high cardiovascular risk categories using the Framingham Risk Score (FRS), Primary Care Equivalents (PCE), or Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) scores. Outcomes included the prevalence of advanced fibrosis (liver stiffness ≥10 kPa), liver stiffness progression (≥20% increase and Baveno category upshift), and LRE (hepatocellular carcinoma, hepatic decompensation, liver transplantation, or liver-related mortality). Associations were assessed using multivariable logistic regression and Fine-Gray competing-risks models. RESULTS: Among 9312 patients with MASLD (mean age, 54.4 ± 11.0 years; 56.8% male; 87.4% Asian), advanced fibrosis prevalence increased with cardiovascular risk: adjusted odds ratios (ORs) were 2.72 (95% confidence interval [CI], 2.25-3.28; P < .001) for FRS, 1.83 (95% CI, 1.46-2.29; P < .001) for PCE, and 2.93 (95% CI, 2.33-3.69; P < .001) for PREVENT. Over a median follow-up of 4.5 years, liver stiffness progression occurred in 5.0% of patients, more frequently in high-risk groups (adjusted subdistribution hazard ratio [SHR], 1.56; 95% CI, 1.14-2.15; P = .006 for PCE and adjusted SHR, 1.85; 95% CI, 1.33-2.56; P < .001 for PREVENT). LREs occurred in 1.4% of patients, with higher incidence in high-risk groups (adjusted SHR, 2.12; 95% CI, 1.19-3.77; P = .010 for FRS; adjusted SHR, 2.01; 95% CI, 1.08-3.74; P = .027 for PCE; and adjusted SHR, 2.80; 95% CI, 1.40-5.61; P = .004 for PREVENT). CONCLUSIONS: Higher cardiovascular risk is associated with greater prevalence of advanced liver fibrosis, liver stiffness progression, and LRE incidence in MASLD.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Zhou XD, Chen QF, Kim SU, et al. Progression of Liver Fibrosis and Liver-Related Event Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease at High Cardiovascular Risk. Clin Gastroenterol Hepatol. 2026. PMID: 41655804. doi:10.1016/j.cgh.2026.01.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。